Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/3513
| Predicate | Object |
|---|---|
| rdf:type | |
| rdfs:label |
Ringers and Dextrose (Injection, Solution)
|
| dailymed-instance:dosage |
As directed by a
physician. Dosage is dependent upon the age, weight and clinical
condition of the patient as well as laboratory determinations. Parenteral drug
products should be inspected visually for particulate matter and
discoloration prior to administration whenever solution and container permit. All injections in
VIAFLEX plastic containers are intended for intravenous administration
using sterile equipment. Additives may be
incompatible. Complete information is not available. Those additives
known to be incompatible should not be used. Consult with pharmacist, if
available. If, in the informed judgement of the physician, it is deemed
advisable to introduce additives, use aseptic technique. Mix thoroughly
when additives have been introduced. Do not store solutions containing
additives.
|
| dailymed-instance:descripti... |
Ringer's and 5%
Dextrose Injection, USP is sterile, nonpyrogenic solution for fluid and
electrolyte replenishment and caloric supply in a single dose container
for intravenous administration. Each 100 mL contains 5 g Dextrose
Hydrous, USP*; 860 mg of Sodium Chloride, USP (NaCl); 33 mg of Calcium
Chloride, USP (CaCl���2HO); and 30 mg of Potassium Chloride, USP (KCl).
It contains no antimicrobial agents. The pH is 4.0 (3.5 to 6.5). Ringer's and 5%
Dextrose Injection, USP administered intravenously has value as a source
of water, electrolytes, and calories. One liter has an ionic
concentration of 147.5 mEq sodium, 4.5 mEq calcium, 4 mEq potassium, and 156 mEq chloride. The osmolarity is 561 mOsmol/L (calc). Normal
physiologic range is approximately 280 to 310 mOsmol/L. Administration
of substantially hypertonic solutions may cause vein damage. The caloric
content is 170 kcal/L. The VIAFLEX plastic container is fabricated from a specially formulated polyvinyl chloride
(PL 146 Plastic). The amount of water that can permeate from inside the
container into the overwrap is insufficient to affect the solution
significantly. Solutions in contact with the plastic container can leach
out certain of its chemical components in very small amounts within the
expiration period, e.g., di-2-ethylhexyl phthalate (DEHP), up to 5 parts
per million. However, the safety of the plastic has been
confirmed in tests in animals according to USP biological tests for
plastic containers as well as by tissue culture toxicity
studies.
|
| dailymed-instance:clinicalP... |
Ringer's and 5%
Dextrose Injection, USP has value as a source of water, electrolytes,
and calories. It is capable of inducing diuresis depending on the
clinical condition of the patient.
|
| dailymed-instance:activeIng... | |
| dailymed-instance:contraind... |
Solutions
containing dextrose may be contraindicated in patients with known
allergy to corn or corn products
|
| dailymed-instance:supply |
Ringer's and 5%
Dextrose Injection, USP in VIAFLEX plastic containers is available as
shown below: Exposure of
pharmaceutical products to heat should be minimized. Avoid excessive
heat. It is recommended the product be stored at room temperature
(25��C): brief exposure up to 40��C does not adversely affect the
product.
|
| dailymed-instance:activeMoi... | |
| dailymed-instance:inactiveI... | |
| dailymed-instance:precautio... |
Clinical evaluation
and periodic laboratory determinations are necessary to monitor changes
in fluid balance, electrolyte concentrations, and acid base balance during prolonged parenteral therapy or whenever the condition of the
patient warrants such evaluation. Caution must be
exercised in the administration of Ringer's and 5% Dextrose Injection,
USP to patients receiving corticosteroids or corticotropin. Ringer's and 5%
Dextrose Injection, USP should be used with caution in patients with
overt or subclinical diabetes mellitus.<br/>Carcinogenesis and
Mutagenesis and Impairment of Fertility: Studies
with Ringer's and 5% Dextrose Injection, USP have not been
performed to evaluate carcinogenic potential, mutagenic
potential, or effects on fertility.<br/>Pregnancy:<br/>Teratogenic
Effects:<br/>Nursing Mothers: It is not
known whether this drug is excreted in human milk. Because many
drugs are excreted in human milk, caution should be exercised
when Ringer's and 5% Dextrose Injection, USP is administered to
a nursing woman.<br/>Pediatric Use: Safety and
effectiveness of Ringer's and 5% Dextrose Injection, USP in
pediatric patients have not been established by adequate and
well controlled trials, however, the use of ringer's and
dextrose solutions in the pediatric population is referenced in
the medical literature. The warnings, precautions and adverse
reactions identified in the label copy should be observed in the
pediatric population. In very low
birth weight infants, excessive or rapid administration of
dextrose injection may result in increased serum osmolality and
possible hemorrhage<br/>Geriatric Use: Clinical
studies of Ringer's and 5% Dextrose Injection, USP did not
include sufficient numbers of subjects aged 65 and over to
determine whether they respond differently from younger
subjects. Other reported clinical experience has not identified
differences in responses between the elderly and younger
patients. In general, dose selection for an elderly patient
should be cautious, usually starting at the low end of the
dosing range, reflecting the greater frequency of decreased
hepatic, renal, or cardiac function, and of concomitant disease
or drug therapy. Do not
administer unless solution is clear and the seal is
intact
|
| dailymed-instance:genericMe... |
Sodium chloride, calcium chloride, potassium chloride and dextrose
|
| dailymed-instance:fullName |
Ringers and Dextrose (Injection, Solution)
|
| dailymed-instance:adverseRe... |
Reactions which may
occur because of the solution or the technique of administration include
febrile response, infection at the site of injection, venous thrombosis
or phlebitis extending from the site of injection, extravasation, and
hypervolemia. If an adverse
reaction does occur, discontinue the infusion, evaluate the patient,
institute appropriate therapeutic countermeasures, and save the
remainder of the fluid for examination if deemed necessary.
|
| dailymed-instance:warning |
Ringer's and 5%
Dextrose Injection, USP should be used with great care, if at all, in
patients with congestive heart failure, severe renal insufficiency, and
in clinical states in which there exists edema with sodium retention. Ringer's and 5%
Dextrose Injection, USP should be used with great care, if at all, in
patients with hyperkalemia, severe renal failure, and in conditions in
which potassium retention is present. Ringer's and 5%
Dextrose Injection, USP should not be administered simultaneously with
blood through the same administration set because of the likelihood of
coagulation. The intravenous
administration of Ringer's and 5% Dextrose Injection, USP can cause
fluid and/or solute overloading resulting in dilution of serum
electrolyte concentrations, overhydration, congested states, or
pulmonary edema. The risk of dilutional states is inversely proportional
to the electrolyte concentrations of the injection. The risk of solute
overload causing congested states with peripheral and pulmonary edema is
directly proportional to the electrolyte concentrations of the
injection. In patients with
diminished renal function, administration of Ringer's and 5% Dextrose
Injection, USP may result in sodium or potassium retention.
|
| dailymed-instance:indicatio... |
Ringer's and 5%
Dextrose Injection, USP is indicated as a source of water, electrolytes
and calories.
|
| dailymed-instance:represent... | |
| dailymed-instance:routeOfAd... | |
| dailymed-instance:name |
Ringers and Dextrose
|